SHC · Sotera Health Co
$18.89
-0.13 (-0.68%)
At close · Aug 14
Market Cap
$5.39B
Shares
285.37M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$18.89
Open$18.96
Day$18.78–18.98
52W close$13.13–19.35
Avg vol 30d3.0M
Short int14.4M · 5.0% float · 4.8d
Short vol63%
Last earningsAug 6, 2026
DataNov 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+14%
above
Price vs 50-day avg
+8%
above
RSI (14)
63
neutral
MACD trend
Positive
52-week position
93%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+8%
trailing
YTD return
+7%
this year
Relative strength
−6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $17 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +58 funds added
Insider flow
Distributing
Net -$2.8M over 90 days · 100% sells
Short interest
Falling
5.04% of float · ▼ -9.2% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
314 holders — near 3-yr high, broad support
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
+6%
Y/Y
Gross margin
55%
expanding
EPS growth
+69%
Y/Y
Free cash flow
$149.2M
Valuation
P/E 33.1
in line
Balance sheet
$1.8B
net debt
Quant / Vol
risk profile
Volatility
29%
annualized · 1-yr
Max drawdown
−32%
past year
ATR
2.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Net revenues
· Full-Year 2026
$1.24B – $1.25B
Adjusted EBITDA
· Full-Year 2026
Non-GAAP
$634M – $643M
Tax rate applicable to Adjusted Net Income
· Full-Year 2026
Non-GAAP
27% – 28%
Adjusted EPS
· Full-Year 2026
Non-GAAP
$0.95 – $1.01
Interest expense
· Full-Year 2026
$135M – $142M
Capital expenditures
· Full-Year 2026
$200M – $225M
Prior guidance
period ended
· from the Earnings Call filed Jun 30, 2025
Constant currency revenue growth
· 2025 full year
4.5% – 6%
Constant currency adjusted EBITDA growth
· 2025 full year
6% – 7.5%
Guided vs delivered
· last 1 settled
Adjusted EPS
full year 2024
guided $0.67 – $0.75
$0.16
Miss −77.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+14%
Bullish
Price vs 50-day avg
+8%
Bullish
RSI (14)
63
Neutral
MACD trend
Positive
Bullish
52-week position
93%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $17 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +58 funds added
Insider flow
Distributing
Net -$2.8M over 90 days · 100% sells
Short interest
Falling
5.04% of float · ▼ -9.2% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
314 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13
Now $19 · 93%
Range high $19
vs 200-day avg +14%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings per share - Basic non-GAAP | $0.44 | Six Months Ended June 30, 2026 | — |
| Adjusted earnings per share - Diluted non-GAAP | $0.44 | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | 621.62M | Twelve Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted EBITDA Margin non-GAAP | 51.1% | Twelve Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted EPS non-GAAP | $0.86 | Full-year 2025 | — |
| Net Leverage non-GAAP | 3.2 | Full-year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SHC
this stock
Sotera Health Co
|
$5.39B | +7.1% | +5.7% | 33.1 | 5.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$222.96B | +1.5% | +14.5% | 32.4 | 1.3% |
|
DHR
Danaher Corp /De/
|
$142.32B | -11.6% | +8.5% | 35.9 | 1.7% |
|
NTRA
Natera, Inc.
|
$44.67B | +35.3% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.41B | -18.6% | +10.4% | 38.7 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SHC | +0.2% | +6.4% | +8.0% | +5.8% | +7.1% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -0.2% | +2.0% | -5.8% | +1.9% | -6.8% |
Key facts
CIK
1822479
CUSIP
83601L102
13F (30d)
304 filings
297 filers
Visit website
Investor relations